Eiger Biopharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
EIGR Nasdaq 8731 https://www.eigerbio.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Eiger Biopharmaceuticals Inc

Investors Holding Back On Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) - May 31st, 2023 11:25 am
Eiger BioPharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update - May 11th, 2023 8:00 pm
Eiger BioPharmaceuticals (NASDAQ:EIGR) adds US$9.4m to market cap in the past 7 days, though investors from five years ago are still down 88% - May 4th, 2023 10:49 am
Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - May 3rd, 2023 8:05 pm
Eiger BioPharmaceuticals Strengthens Management Team with New Appointments - Apr 13th, 2023 12:00 pm
Some Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Analysts Just Made A Major Cut To Next Year's Estimates - Mar 31st, 2023 10:17 am
Loss-Making Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Expected To Breakeven In The Medium-Term - Mar 18th, 2023 12:40 pm
Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update - Mar 16th, 2023 8:28 pm
Eiger BioPharma's Single Dose Of Peginterferon Lambda Cuts Risk Of COVID-19-Related Hospitalizations, Deaths - Feb 9th, 2023 5:32 pm
New England Journal of Medicine Publishes Positive Phase 3 TOGETHER Results with Peginterferon Lambda in COVID-19 - Feb 8th, 2023 10:00 pm
The Scientific Founder & Independent Director of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), Jeffrey Glenn, Just Bought 43% More Shares - Dec 29th, 2022 10:15 am
Newsflash: Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Analysts Have Been Trimming Their Revenue Forecasts - Dec 20th, 2022 10:02 am
Eiger BioPharmaceuticals Announces Leadership Change - Dec 15th, 2022 10:45 pm
Eiger Announces Both Lonafarnib-based Treatments in Pivotal Phase 3 D-LIVR Trial in Hepatitis Delta Virus (HDV) Achieved Statistical Significance Against Placebo in Composite Primary Endpoint - Dec 8th, 2022 1:00 pm
Eiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 D-LIVR Study Results of Lonafarnib-based Treatments in Hepatitis Delta Virus (HDV) on Thursday, December 8, 2022 - Dec 7th, 2022 9:05 pm
Eiger BioPharmaceuticals Third Quarter 2022 Earnings: Misses Expectations - Nov 9th, 2022 11:15 am
Eiger BioPharmaceuticals to Participate in Upcoming Investor Conferences - Nov 8th, 2022 9:05 pm
Eiger BioPharmaceuticals (EIGR) Reports Q3 Loss, Tops Revenue Estimates - Nov 3rd, 2022 9:55 pm
Eiger BioPharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update - Nov 3rd, 2022 8:01 pm
Scale The Eiger With This 'Sum of the Parts Trade - Oct 30th, 2022 1:00 pm